Search Results - "Haanen, John"

Converting Cold into Hot Tumors by Combining Immunotherapies by Haanen, John B.A.G.

“…In a small phase Ib study in this issue of Cell, Ribas et al. report that the combination of intralesional injection of a modified human herpes simplex virus…”
Get full text

Adoptive cellular therapies: the current landscape by Rohaan, Maartje W., Wilgenhof, Sofie, Haanen, John B. A. G.

“…For many cancer types, the immune system plays an essential role in their development and growth. Based on these rather novel insights, immunotherapeutic…”
Get full text

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer by Voabil, Paula, de Bruijn, Marjolein, Roelofsen, Lisanne M., Hendriks, Sanne H., Brokamp, Simone, van den Braber, Marlous, Broeks, Annegien, Sanders, Joyce, Herzig, Petra, Zippelius, Alfred, Blank, Christian U., Hartemink, Koen J., Monkhorst, Kim, Haanen, John B.A.G., Schumacher, Ton N., Thommen, Daniela S.

“…Inhibitors of the PD-1–PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little…”
Get full text

Cancer immunotherapy – revisited by Punt, Cornelis J. A, Lesterhuis, W. Joost, Haanen, John B. A. G

“…Key Points Clinical development of immunotherapy has been hampered by the complexity of defining the optimal dose and schedule, and the lack of financial…”
Get full text

Clinical advances and ongoing trials of mRNA vaccines for cancer treatment by Lorentzen, Cathrine Lund, Haanen, John B, Met, Özcan, Svane, Inge Marie

“…Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines…”
Get full text

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma by Li, Hanjie, van der Leun, Anne M., Yofe, Ido, Lubling, Yaniv, Gelbard-Solodkin, Dikla, van Akkooi, Alexander C.J., van den Braber, Marlous, Rozeman, Elisa A., Haanen, John B.A.G., Blank, Christian U., Horlings, Hugo M., David, Eyal, Baran, Yael, Bercovich, Akhiad, Lifshitz, Aviezer, Schumacher, Ton N., Tanay, Amos, Amit, Ido

“…Tumor immune cell compositions play a major role in response to immunotherapy, but the heterogeneity and dynamics of immune infiltrates in human cancer lesions…”
Get full text

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors by Kostine, Marie, Finckh, Axel, Bingham, Clifton O, Visser, Karen, Leipe, Jan, Schulze-Koops, Hendrik, Choy, Ernest H, Benesova, Karolina, Radstake, Timothy R D J, Cope, Andrew P, Lambotte, Olivier, Gottenberg, Jacques-Eric, Allenbach, Yves, Visser, Marianne, Rusthoven, Cindy, Thomasen, Lone, Jamal, Shahin, Marabelle, Aurélien, Larkin, James, Haanen, John B A G, Calabrese, Leonard H, Mariette, Xavier, Schaeverbeke, Thierry

“…Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs)…”
Get more information

Minus Times Minus Equals Plus by Haanen, John, Peters, Solange

Get full text

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers by Scheper, Wouter, Kelderman, Sander, Fanchi, Lorenzo F., Linnemann, Carsten, Bendle, Gavin, de Rooij, Marije A. J., Hirt, Christian, Mezzadra, Riccardo, Slagter, Maarten, Dijkstra, Krijn, Kluin, Roelof J. C., Snaebjornsson, Petur, Milne, Katy, Nelson, Brad H., Zijlmans, Henry, Kenter, Gemma, Voest, Emile E., Haanen, John B. A. G., Schumacher, Ton N.

“…Infiltration of human cancers by T cells is generally interpreted as a sign of immune recognition, and there is a growing effort to reactivate dysfunctional T…”
Get full text

Neoantigen landscape dynamics during human melanoma–T cell interactions by Verdegaal, Els M. E., de Miranda, Noel F. C. C., Visser, Marten, Harryvan, Tom, van Buuren, Marit M., Andersen, Rikke S., Hadrup, Sine R., van der Minne, Caroline E., Schotte, Remko, Spits, Hergen, Haanen, John B. A. G., Kapiteijn, Ellen H. W., Schumacher, Ton N., van der Burg, Sjoerd H.

“…Analyses of tumour samples and tumour-infiltrating lymphocytes from two patients with melanoma who were treated with adoptive T-cell therapy provide evidence…”
Get full text

The "cancer immunogram" by Blank, Christian U., Haanen, John B., Ribas, Antoni, Schumacher, Ton N.

“…Visualizing the state of cancer–immune system interactions may spur personalized therapy The impact of cancer immunotherapy on clinical cancer care is growing…”
Get full text

NKG2A, a New Kid on the Immune Checkpoint Block by Haanen, John B., Cerundolo, Vincenzo

“…One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine…”
Get full text

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial by Mackensen, Andreas, Haanen, John B.A.G., Koenecke, Christian, Alsdorf, Winfried, Wagner-Drouet, Eva, Borchmann, Peter, Heudobler, Daniel, Ferstl, Barbara, Klobuch, Sebastian, Bokemeyer, Carsten, Desuki, Alexander, Lüke, Florian, Kutsch, Nadine, Müller, Fabian, Smit, Eveline, Hillemanns, Peter, Karagiannis, Panagiotis, Wiegert, Erol, He, Ying, Ho, Thang, Kang-Fortner, Qing, Schlitter, Anna Melissa, Schulz-Eying, Catrine, Finlayson, Andrew, Flemmig, Carina, Kühlcke, Klaus, Preußner, Liane, Rengstl, Benjamin, Türeci, Özlem, Şahin, Uğur

“…The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, and could be a promising treatment target. We report dose…”
Get full text

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma by Blank, Christian U., Rozeman, Elisa A., Fanchi, Lorenzo F., Sikorska, Karolina, van de Wiel, Bart, Kvistborg, Pia, Krijgsman, Oscar, van den Braber, Marlous, Philips, Daisy, Broeks, Annegien, van Thienen, Johannes V., Mallo, Henk A., Adriaansz, Sandra, ter Meulen, Sylvia, Pronk, Loes M., Grijpink-Ongering, Lindsay G., Bruining, Annemarie, Gittelman, Rachel M., Warren, Sarah, van Tinteren, Harm, Peeper, Daniel S., Haanen, John B. A. G., van Akkooi, Alexander C. J., Schumacher, Ton N.

“…Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients 1 , 2 . In stage IV disease, the…”
Get full text

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma by Wolchok, Jedd D, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Lao, Christopher D, Cowey, C Lance, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier Francesco, Smylie, Michael, Butler, Marcus O, Hill, Andrew, Márquez-Rodas, Ivan, Haanen, John B A G, Guidoboni, Massimo, Maio, Michele, Schöffski, Patrick, Carlino, Matteo S, Lebbé, Céleste, McArthur, Grant, Ascierto, Paolo A, Daniels, Gregory A, Long, Georgina V, Bas, Tuba, Ritchings, Corey, Larkin, James, Hodi, F Stephen

“…In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus…”
Get full text

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial by Voorwerk, Leonie, Slagter, Maarten, Horlings, Hugo M., Sikorska, Karolina, van de Vijver, Koen K., de Maaker, Michiel, Nederlof, Iris, Kluin, Roelof J. C., Warren, Sarah, Ong, SuFey, Wiersma, Terry G., Russell, Nicola S., Lalezari, Ferry, Schouten, Philip C., Bakker, Noor A. M., Ketelaars, Steven L. C., Peters, Dennis, Lange, Charlotte A. H., van Werkhoven, Erik, van Tinteren, Harm, Mandjes, Ingrid A. M., Kemper, Inge, Onderwater, Suzanne, Chalabi, Myriam, Wilgenhof, Sofie, Haanen, John B. A. G., Salgado, Roberto, de Visser, Karin E., Sonke, Gabe S., Wessels, Lodewyk F. A., Linn, Sabine C., Schumacher, Ton N., Blank, Christian U., Kok, Marleen

“…The efficacy of programmed cell death protein 1 (PD-1) blockade in metastatic triple-negative breast cancer (TNBC) is low 1 – 5 , highlighting a need for…”
Get full text

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option by Rohaan, Maartje W, van den Berg, Joost H, Kvistborg, Pia, Haanen, John B A G

“…The treatment of metastatic melanoma patients with autologous tumor-infiltrating lymphocytes (TIL) shows robust, reproducible, clinical responses in clinical…”
Get full text

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma by Klobuch, Sebastian, Seijkens, Tom T. P., Schumacher, Ton N., Haanen, John B. A. G.

“…Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapy with BRAF and MEK inhibitors have revolutionized the treatment of melanoma over the…”
Get full text

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma by Guislain, Aurelie, Gadiot, Jules, Kaiser, Andrew, Jordanova, Ekaterina S., Broeks, Annegien, Sanders, Joyce, van Boven, Hester, de Gruijl, Tanja D., Haanen, John B. A. G., Bex, Axel, Blank, Christian U.

“…Targeted therapy with sunitinib, pazopanib or everolimus has improved treatment outcome for patients with metastatic renal cell carcinoma patients (RCC)…”
Get full text

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials by Schadendorf, Dirk, Long, Georgina V., Stroiakovski, Daniil, Karaszewska, Boguslawa, Hauschild, Axel, Levchenko, Evgeny, Chiarion-Sileni, Vanna, Schachter, Jacob, Garbe, Claus, Dutriaux, Caroline, Gogas, Helen, Mandalà, Mario, Haanen, John B.A.G., Lebbé, Céleste, Mackiewicz, Andrzej, Rutkowski, Piotr, Grob, Jean-Jacques, Nathan, Paul, Ribas, Antoni, Davies, Michael A., Zhang, Ying, Kaper, Mathilde, Mookerjee, Bijoyesh, Legos, Jeffrey J., Flaherty, Keith T., Robert, Caroline

“…Understanding predictors of long-term benefit with currently available melanoma therapies is the key for optimising individualised treatments. A prior pooled…”
Get full text